IGF2 and ovarian cancer: An animal experiment shows that dexmedetomidine (50) effectively inhibits insulin-like growth factor 2 (IGF2) signaling pathway activation in ovarian cancer rats, thereby enhancing their immune function and suppressing the invasion and migration of ovarian cancer cells.